Literature DB >> 16388482

Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens.

Katalin A Wilkinson1, Onn M Kon, Sandra M Newton, Graeme Meintjes, Robert N Davidson, Geoffrey Pasvol, Robert J Wilkinson.   

Abstract

Most cases of latent tuberculosis infection (LTBI) do not cause symptoms during the lifetime of the infected person. Longitudinal analysis of the immune response of healthy Mycobacterium tuberculosis-infected people might, therefore, give insight into the basis of protective immunity. In a longitudinal study, we documented the effect that treatment had on the T cell response to M. tuberculosis antigens in 33 healthy people with LTBI. Preventive treatment of LTBI resulted in a 1.8-fold average increase in the numbers of interferon (IFN)- gamma -producing T cells within 26 +/- 4 days (P = .006), followed by a decrease by the end of the treatment period (82 +/- 6 days; P = .004). There was no significant overall change in the T cell response to any antigen in a control group (n = 8) of patients who elected radiological follow-up. Using live M. tuberculosis strain H37Rv as a stimulant in an enzyme-linked immunospot assay in sensitized individuals, we showed that isoniazid, but not rifampin, led to an increase in the number of IFN- gamma -producing cells. These results suggest that the integrity of the bacterial cell wall is important for M. tuberculosis in avoiding immune recognition by T cells and favor a dynamic model of LTBI.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16388482     DOI: 10.1086/499311

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  51 in total

1.  Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease.

Authors:  S A Clark; S L Martin; A Pozniak; A Steel; B Ward; J Dunning; D C Henderson; M Nelson; B Gazzard; P Kelleher
Journal:  Clin Exp Immunol       Date:  2007-08-02       Impact factor: 4.330

2.  Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.

Authors:  Clare R Sander; Ansar A Pathan; Natalie E R Beveridge; Ian Poulton; Angela Minassian; Nicola Alder; Johan Van Wijgerden; Adrian V S Hill; Fergus V Gleeson; Robert J O Davies; Geoffrey Pasvol; Helen McShane
Journal:  Am J Respir Crit Care Med       Date:  2009-01-16       Impact factor: 21.405

3.  Combinatorial Immunoprofiling in Latent Tuberculosis Infection. Toward Better Risk Stratification.

Authors:  Patricio Escalante; Tobias Peikert; Virginia P Van Keulen; Courtney L Erskine; Cathy L Bornhorst; Boleyn R Andrist; Kevin McCoy; Larry R Pease; Roshini S Abraham; Keith L Knutson; Hirohito Kita; Adam G Schrum; Andrew H Limper
Journal:  Am J Respir Crit Care Med       Date:  2015-09-01       Impact factor: 21.405

4.  Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals.

Authors:  Annie F Luetkemeyer; Edwin D Charlebois; Laura L Flores; David R Bangsberg; Steven G Deeks; Jeffrey N Martin; Diane V Havlir
Journal:  Am J Respir Crit Care Med       Date:  2007-01-11       Impact factor: 21.405

5.  Evaluation of the effect of treatment of latent tuberculosis infection on QuantiFERON-TB gold assay results.

Authors:  Nira R Pollock; Suely S Kashino; Danielle R Napolitano; Alex Sloutsky; Swati Joshi; Jasmine Guillet; Michael Wong; Edward Nardell; Antonio Campos-Neto
Journal:  Infect Control Hosp Epidemiol       Date:  2009-04       Impact factor: 3.254

6.  Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.

Authors:  Mark Hatherill; Hendrik Geldenhuys; Bernadette Pienaar; Sara Suliman; Phalkun Chheng; Sara M Debanne; Daniel F Hoft; W Henry Boom; Willem A Hanekom; John L Johnson
Journal:  Vaccine       Date:  2014-05-09       Impact factor: 3.641

7.  Reversion and conversion of Mycobacterium tuberculosis IFN-gamma ELISpot results during anti-tuberculous treatment in HIV-infected children.

Authors:  Tom G Connell; Mary-Ann Davies; Christine Johannisen; Kathryn Wood; Sandy Pienaar; Katalin A Wilkinson; Robert J Wilkinson; Heather J Zar; David Beatty; Mark P Nicol; Nigel Curtis; Brian Eley
Journal:  BMC Infect Dis       Date:  2010-05-27       Impact factor: 3.090

8.  Decay kinetics of an interferon gamma release assay with anti-tuberculosis therapy in newly diagnosed tuberculosis cases.

Authors:  Ifedayo M O Adetifa; Martin O C Ota; Brigitte Walther; Abdulrahman S Hammond; Moses D Lugos; David J Jeffries; Simon A Donkor; Richard A Adegbola; Philip C Hill
Journal:  PLoS One       Date:  2010-09-01       Impact factor: 3.240

9.  Temporal dynamics of interferon gamma responses in children evaluated for tuberculosis.

Authors:  Jean-Louis Herrmann; Marie Belloy; Raphael Porcher; Nancy Simonney; Rola Aboutaam; Muriel Lebourgeois; Joel Gaudelus; Laure De Losangeles; Katarina Chadelat; Pierre Scheinmann; Nicole Beydon; Brigitte Fauroux; Martine Bingen; Mustapha Terki; Dominique Barraud; Philippe Cruaud; Catherine Offredo; Agnes Ferroni; Patrick Berche; Didier Moissenet; Hoang Vuthien; Catherine Doit; Edouard Bingen; Philippe Henri Lagrange
Journal:  PLoS One       Date:  2009-01-06       Impact factor: 3.240

10.  High-sensitive and rapid detection of Mycobacterium tuberculosis infection by IFN-gamma release assay among HIV-infected individuals in BCG-vaccinated area.

Authors:  Weimin Jiang; Lingyun Shao; Ying Zhang; Shu Zhang; Chengyan Meng; Yunya Xu; Lingli Huang; Yun Wang; Ying Wang; Xinhua Weng; Wenhong Zhang
Journal:  BMC Immunol       Date:  2009-05-28       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.